Tibolone medicamento synthetica steroid cum estrogenic, progestogenic, et debilis androgenicus actus qui introductus est 1988 et late in Europa, Asia, Australasia, et, exceptis Civitatibus Foederatis Americae (ubi non praesto?), Reliqua mundi.
Ponitur maxime ad curationem endometriosis,tum hormone replacement illic in post-menopausalis mulieres. Tibolone similem vel maiorem efficaciam habet ad medicamenta maiora hormona repositum, sed similem partem effectus profile participat. Etiam exploratum est ut curatio possibilis pro dysfunctione sexuali feminino.
Tibolone primus est generis compositorum, quae in regulatoribus activitatis oestrogenicae selectivae texuntur. Structure ad derivationes 19-nortestosterones refertur et oestrogenicos debiles exhibet, progestogenic et androgenic actiones. Tibolone ipsa actio biologica non habet. Diversi effectus hormonales tiboloni proveniunt ex actione plurium metabolitarum clavis in variis fibris.
Tibolone imprimis metabolisus est in δ4,3β-hydroxy et 3α hydroxy isomers.. Hi isomers diversas affinitates habent ligaturas pro estrogen, progesterone androgen receptors1. The 3α?hydroxy et 3β-hydroxy metabolitae solum ligant ad receptorem estrogenium, whereas the δ4 isomer has affinity for the progesterone and androgen receptors, but not for the oestrogen receptor.
Tibolone is a relatively new drug for postmenopausal women, which is structurally related to 19-nortestosterone derivatives and exhibits weak oestrogenic, progestogenic et androgenic actiones. The effect of tibolone on breast tissue is still obscure. In vitro studies have shown conflicting results regarding the effects of tibolone on breast cells.
On the other hand, although epidemiological studies show an increase in the risk of breast cancer among women treated with tibolone, accumulation of data obtained from radiological studies presents promising results. tamen, the safety of tibolone with regard to breast tissue needs to be investigated further, especially through well-designed, large-scale, randomised-controlled trials.
